Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anaplastic Lymphoma Kinase”

148 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 148 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05015010
What this trial is testing

Alectinib in Neo-adjuvant Treatment of Stage III NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Gruppo Oncologico Italiano di Ricerca Clinica 33
Post-approval studies (Phase 4)Active Not RecruitingNCT05160922
What this trial is testing

Crizotinib Continuation Clinical Study

Who this might be right for
NSCLCALCLIMT
Pfizer 27
Early research (Phase 1)Active Not RecruitingNCT03611738
What this trial is testing

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Who this might be right for
Non-small Cell Lung CancerLung CancerNon-small Cell Lung Cancer Metastatic+3 more
H. Lee Moffitt Cancer Center and Research Institute 21
Not applicableActive Not RecruitingNCT06269133
What this trial is testing

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Who this might be right for
Advanced Non-small Cell Lung Cancer
Regeneron Pharmaceuticals 1,000
Early research (Phase 1)Study completedNCT01283516
What this trial is testing

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

Who this might be right for
Tumors Characterized by Genetic Abnormalities of ALK
Novartis Pharmaceuticals 304
Testing effectiveness (Phase 2)Study completedNCT03535740
What this trial is testing

Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

Who this might be right for
ALK-positive Advanced NSCLC
Ariad Pharmaceuticals 103
Not applicableActive Not RecruitingNCT04881916
What this trial is testing

Immune and Genomic Markers in ALK+ NSCLC

Who this might be right for
Anaplastic Lymphoma Kinase Gene TranslocationNon-Small Cell Lung Cancer
Massachusetts General Hospital 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT04318938
What this trial is testing

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Who this might be right for
NSCLC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 118
Not applicableActive Not RecruitingNCT05370469
What this trial is testing

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

Who this might be right for
Lung CancerEGFR Gene MutationEGFR+6 more
University of Virginia 30
Not applicableStudy completedNCT03718117
What this trial is testing

Descriptive Observational Study ALK-2016-CPHG

Who this might be right for
NSCLCCrizotinibALK Gene Rearrangement or ROS1 Gene Rearrangement
Pfizer 73
Not applicableEnded earlyNCT00504205
What this trial is testing

MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma

Who this might be right for
LymphomaUnspecified Adult Solid Tumor, Protocol Specific
Astex Pharmaceuticals, Inc. 30
Large-scale testing (Phase 3)UnknownNCT05204628
What this trial is testing

Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib

Who this might be right for
Non-small Cell Lung Cancer
Xuanzhu Biopharmaceutical Co., Ltd. 238
Post-approval studies (Phase 4)Looking for participantsNCT05525338
What this trial is testing

Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels

Who this might be right for
Drug MonitoringCarcinoma, Non-Small-Cell LungLung Cancer+2 more
University Medical Center Groningen 196
Testing effectiveness (Phase 2)Ended earlyNCT04676360
What this trial is testing

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

Who this might be right for
Relapsed Plasmablastic LymphomaRefractory Plasmablastic LymphomaAnaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma
Jacob Soumerai, MD 10
Not applicableActive Not RecruitingNCT06410040
What this trial is testing

A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis

Who this might be right for
ALK-positive Non-small Cell Lung CancerBrain MetastasesMeningeal Metastasis
Sichuan Cancer Hospital and Research Institute 28
Not applicableNot Yet RecruitingNCT06736561
What this trial is testing

Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients.

Who this might be right for
ALK PositiveEnsartinibNSCLC+1 more
Harbin Medical University 100
Not applicableStudy completedNCT04887519
What this trial is testing

Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell LungAnaplastic Lymphoma Kinase
Takeda 39
Large-scale testing (Phase 3)UnknownNCT04009317
What this trial is testing

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
ALK-positive NSCLC
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 260
Testing effectiveness (Phase 2)Study completedNCT03410108
What this trial is testing

Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
ALK-positive Advanced NSCLC
Takeda 104
Testing effectiveness (Phase 2)Study completedNCT03049618
What this trial is testing

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

Who this might be right for
ALK Gene MutationBRAF Gene MutationEGFR Gene Mutation+9 more
University of Southern California 42
Load More Results